Uncategorized
BioTime Presents Updated OpRegen® Clinical Trial Data at ARVO
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that an abstract related to one of its lead programs, OpRegen® for dry-AMD, was presented at the Association for Research in Vision and Ophthalmology (ARVO) meeting taking place from April 29th – May 3rd, 2018, in Honolulu, Hawaii. Dr. Eyal Banin (Hadassah-Hebrew University Medical Center, Jerusalem, Israel), the presenting author and one